Vicor Technologies, a biotechnology company, is focused on creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i®). The PD2i® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.
Diagnostics that enable inexpensive, accurate, and early identification of disease in at-risk populations prior to costly treatments are garnering increased attention in the current healthcare debate. These populations are significant, representing 12 million at-risk cardiac patients, 23.7 million diabetics, and
38 million trauma incidents
Vicor is currently in the process of commercializing its first three products: PD2i-VS™ (Vital Sign), which quickly evaluates critically-injured soldiers and civilians to improve triage and survivability; PD2i-VS™, which identifies those at risk of sudden cardiac death within the following six months; and PD2i Analyzer™, which measures heartrate variability in patients at rest and in response to controlled exercise and paced respiration.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment